Related references
Note: Only part of the references are listed.UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients
P. Ramachandran et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Treatment failure with new hepatitis C drugs
Vincent Soriano et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals
Patrice Cacoub et al.
JOURNAL OF HEPATOLOGY (2012)
Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?
Mitchell L. Shiffman et al.
LIVER INTERNATIONAL (2012)
Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients
Vincent Soriano et al.
AIDS (2011)
Effect of the Hepatitis C Virus Protease Inhibitor Telaprevir on the Pharmacokinetics of Amlodipine and Atorvastatin
Jee Eun Lee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Drugs in Development for Viral Hepatitis Care and Caution
Paul J. Pockros
DRUGS (2011)
TELAPREVIR-BASED REGIMENS SUBSTANTIALLY IMPROVED SVR RATES ACROSS ALL IL28B GENOTYPES IN THE ADVANCE TRIAL
Ira M. Jacobson et al.
GASTROENTEROLOGY (2011)
Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections
Graham R. Foster et al.
GASTROENTEROLOGY (2011)
Effect of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus
Varun Garg et al.
HEPATOLOGY (2011)
Telaprevir, Boceprevir, Cytochrome P450 and Immunosuppressive Agents - A Potentially Lethal Cocktail
Michael Charlton
HEPATOLOGY (2011)
Genotype Differences in Susceptibility and Resistance Development of Hepatitis C Virus to Protease Inhibitors Telaprevir (VX-950) and Danoprevir (ITMN-191)
Ingrid Imhof et al.
HEPATOLOGY (2011)
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
Marc G. Ghany et al.
HEPATOLOGY (2011)
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
JOURNAL OF HEPATOLOGY (2011)
Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
Kenneth E. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Retreatment of HCV Infection
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions
Kay Seden et al.
CURRENT OPINION IN HIV AND AIDS (2011)
Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or-2b to Patients With Chronic Hepatitis C
Patrick Marcellin et al.
GASTROENTEROLOGY (2011)
Characterization of V36C, a Novel Amino Acid Substitution Conferring Hepatitis C Virus (HCV) Resistance to Telaprevir, a Potent Peptidomimetic Inhibitor of HCV Protease
Laetitia Barbotte et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Susceptibility of Treatment-Naive Hepatitis C Virus (HCV) Clinical Isolates to HCV Protease Inhibitors
Andrew Bae et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression
Gary L. Davis et al.
GASTROENTEROLOGY (2010)
Amino Acid Substitution in Hepatitis C Virus Core Region and Genetic Variation Near the Interleukin 28B Gene Predict Viral Response to Telaprevir with Peginterferon and Ribavirin
Norio Akuta et al.
HEPATOLOGY (2010)
Telaprevir for Previously Treated Chronic HCV Infection.
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796
Matthew F. McCown et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Diagnosis, Management, and Treatment of Hepatitis C: An Update
Marc G. Ghany et al.
HEPATOLOGY (2009)
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
Christophe Hezode et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Review: Therapeutic implications of hepatitis C virus resistance to antiviral drugs
Jean-Michel Pawlotsky
Therapeutic Advances in Gastroenterology (2009)
Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus
Christoph Welsch et al.
GENOME BIOLOGY (2008)
Phenotypic characterization of resistant Val(36) variants of hepatitis C virus NS3-4A serine protease
Yi Zhou et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients
Tara L. Kieffer et al.
HEPATOLOGY (2007)
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir
Christoph Sarrazin et al.
GASTROENTEROLOGY (2007)
VX-950, a novel hepatitis C virus (HCV) NS34A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells
K Lin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease
RB Perni et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Share Paper
